ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Shattuck Labs (STTK)
Shattuck Labs stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$5.77▲ +4.15%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Shattuck Labs in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Shattuck Labs
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Shattuck Labs a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $5.01 and $6.44; in 9 out of 10, between $4.01 and $8.04. Estimated annual volatility is 68%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $675M
- 52-week high
- $8.33
- 52-week low
- $1.72
- Revenue (12 months)
- $1.0M
- Revenue growth (YoY)
- -82.5%
- Gross margin
- 0.0%
- Return on equity
- -39.2%
- Free cash flow (12 months)
- $-21.2M
- Beta
- 1.10
What this means
ATLAS does not publish a fair value for STTK right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks STTK has traded between $1.72 and $8.33. Today it is 30.7% below that high and 235% above its low.
Its beta is 1.10: it moves roughly in line with the market.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases.
Want to see everything about Shattuck Labs?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Shattuck Labs do?
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases.
What is the chance STTK goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, STTK ends the month between $5.01 and $6.44.
How big is Shattuck Labs and what is its P/E ratio?
Shattuck Labs's market capitalization is $675M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is STTK?
ATLAS estimates annual volatility at 68%. In a typical month, half of the outcomes end between $5.01 and $6.44.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer